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Abstract This dose-ranging study was conducted to
identify the optimal fixed dose of lipegfilgrastim compared
with pegfilgrastim 6.0 mg for the provision of neutrophil
support during myelosuppressive chemotherapy in patients
with breast cancer. A phase 2 study was conducted in
which 208 chemotherapy-naive patients were randomized
to receive lipegfilgrastim 3.0, 4.5, or 6.0 mg or pegfilgra-
stim 6.0 mg. Study drugs were administered as a single
subcutaneous injection on day 2 of each chemotherapy
cycle (doxorubicin/docetaxel on day 1 for four 3-week
cycles). The primary outcome measure was duration of
severe neutropenia (DSN) in cycle 1. Patients treated with
lipegfilgrastim experienced shorter DSN in cycle 1 with
higher doses. The mean DSN was 0.76 days in the lipeg-
filgrastim 6.0-mg group and 0.87 days in the pegfilgrastim
6.0-mg group, with no significant differences between
treatment groups. Treatment with lipegfilgrastim 6.0 mg
was consistently associated with a higher absolute neutro-
phil count (ANC) at nadir, shorter ANC recovery time, and
a similar safety and tolerability profile compared with
pegfilgrastim. This phase 2 study demonstrated that
lipegfilgrastim 6.0 mg is the optimal dose for patients with
breast cancer and provides neutrophil support that is at
least equivalent to the standard 6.0-mg fixed dose of
pegfilgrastim.
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ANC Absolute neutrophil count
AUC Area under the concentration–time curve
CI Confidence interval
Cmax Maximum serum concentration
DSN Duration of severe neutropenia
ECOG Eastern Cooperative Oncology Group
FN Febrile neutropenia






TEAE Treatment-emergent adverse event
TEADR Treatment-emergent adverse drug reaction
T Apparent terminal elimination half-life
Tmax Time to Cmax
Introduction
Neutropenia is a frequent, dose-limiting complication in
cancer patients receiving myelosuppressive chemotherapy.
Patients with neutropenia have increased risk of potentially
life-threatening infections that require hospitalization and
treatment with intravenous (i.v.) antibiotics [1]. Conse-
quently, patients who develop severe or febrile neutropenia
(FN) during chemotherapy generally experience dose reduc-
tions or delays, which may compromise treatment success [2].
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Granulocyte colony-stimulating factors (G-CSFs)
enhance the number and function of circulating neutrophils
[3]. Prophylactic G-CSF is routinely recommended for
patients receiving chemotherapy regimens associated with
C20 % risk of FN [2, 4, 5]. Individual risk factors for
neutropenic complications also should be considered when
assessing use of prophylactic G-CSF in patients receiving a
chemotherapy regimen associated with a 10–20 % risk of
FN [2, 4].
Filgrastim is the first Escherichia coli–derived nongly-
cosylated recombinant form of human G-CSF [6]. Pegfil-
grastim (Neulasta; Amgen Inc., Thousand Oaks, CA) is
created by the covalent attachment of a polyethylene glycol
(PEG) moiety to filgrastim [7]. The addition of the PEG
moiety extends the half-life, allowing for dosing once per
chemotherapy cycle [7]. The improved dosing regimen
reduces the overall number of doses required [8] and is
expected to improve the quality of life of patients by
decreasing the burden associated with daily dosing [9].
Lipegfilgrastim (Lonquex; Teva Pharmaceuticals,
Petach Tikva, Israel) is a once-per-cycle, glycoPEGylated
recombinant human G-CSF that is approved by the Euro-
pean Medicines Agency for reducing the duration of neu-
tropenia and the incidence of FN in adults treated with
cytotoxic chemotherapy for malignancy (with the excep-
tion of chronic myeloid leukemia and myelodysplastic
syndromes) [10]. A recent phase 3 trial demonstrated that
lipegfilgrastim was as effective as pegfilgrastim in reducing
neutropenia in patients with breast cancer receiving
myelosuppressive chemotherapy [11].
The primary objective of this dose-ranging phase 2
study was to compare lipegfilgrastim with a 6.0-mg dose of
pegfilgrastim to identify the optimal fixed dose of lipeg-
filgrastim to reduce the duration of severe neutropenia
(DSN) in patients with primary breast cancer receiving




This multinational, multicenter, double-blind study con-
ducted between June 2008 and November 2008 included
229 patients screened and enrolled at 37 centers in the
Czech Republic, Germany, Hungary, Romania, Russia, and
Ukraine. The study was designed in accordance with
therapeutic guidelines and recommendations proposed by
the American Society of Clinical Oncology [5], in line with
current relevant guidelines from the European Society of
Medical Oncology [12] and European Medicines Agency
[13], and was conducted in accordance with the
Declaration of Helsinki and the International Conference
on Harmonisation guidance for Good Clinical Practice.
It was approved by local institutional review boards/inde-
pendent ethics committees of participating centers. A
written informed consent was obtained from all patients.
This 12-week double-blind study comprised four 3-week
chemotherapy cycles. Patients were randomized 1:1:1:1 to
receive 3.0, 4.5, or 6.0 mg lipegfilgrastim or 6.0 mg peg-
filgrastim subcutaneously on chemotherapy day 2 (&24 h
after start of chemotherapy). Lipegfilgrastim doses were
based on phase 1 results in which dosing was adjusted
based on the body weight of patients. Patients were ran-
domized in blocks and stratified by country, reason for
chemotherapy (adjuvant therapy/metastatic disease), and
body weight.
A true double-blind design was not feasible because
lipegfilgrastim was provided in vials and pegfilgrastim in
prefilled syringes; therefore, study drug was administered
by qualified, unblinded personnel. Every effort was made
to ensure that patients remained blinded. Investigators were
kept blinded and performed all patient assessments without
any knowledge of treatment assignment.
Patients
Male and female patients C18 years of age with high-risk
stage II, III, or IV breast cancer (according to the American
Joint Committee on Cancer [14]) were eligible if they had
an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status B2; absolute neutrophil count (ANC)
C1.5 9 109/L; platelet count C100 9 109/L; and adequate
cardiac, hepatic, and renal function. Patients had to be
chemotherapy-naive and eligible for or scheduled to
receive doxorubicin/docetaxel as routine chemotherapy.
Exclusion criteria included previous G-CSF exposure,
known docetaxel hypersensitivity, Cgrade 2 underlying
neuropathy, treatment with systemically active antibiotics
within 72 h before chemotherapy, treatment with lithium,
chronic oral corticosteroid use, or radiation therapy within
4 weeks of randomization, prior bone marrow or stem
cell transplantation, or malignancy within 5 years. Also
excluded were pregnant or breastfeeding women and
women of childbearing potential who did not agree to use
an effective method of contraception.
Chemotherapy treatment
Chemotherapy consisted of doxorubicin 60 mg/m2 given as
an i.v. bolus injection followed 1 h later by a 1-h i.v.
infusion of docetaxel 75 mg/m2. Treatment was repeated
every 21 days for up to four cycles. To begin full-dose
chemotherapy on day 1 of the next cycle (day 22 of pre-
vious cycle), ANC must have recovered to C1.5 9 109/L
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and platelet counts to C100 9 109/L. If these requirements
were not met, postponement of the following cycle for up
to 2 weeks was acceptable. Both ANC and platelets were
determined on day 15 of each cycle by a central laboratory
(EurofinsMedinet, The Netherlands) so that results were
available at the beginning of the next cycle.
In patients who experienced FN and/or ANC \0.5 9
109/L for [1 week, severe or cumulative cutaneous reac-
tions, or severe (grade 3 or 4) peripheral neuropathy during
therapy, the dose of docetaxel was reduced by 20 %.
Doxorubicin was reduced by 25 % in patients with FN and/
or ANC \0.5 9 109/L for [1 week. In patients with a
platelet count of \20 9 109/L and/or failure to recover to
C100 9 109/L by day 21 of a cycle, dosages of doxoru-
bicin and docetaxel had to be reduced by 25 % in sub-
sequent cycles. If reactions continued at the reduced
chemotherapy doses, study treatment was discontinued and
the patient was withdrawn.
Efficacy measurements
Blood samples for ANC were collected within 24 h before
chemotherapy in cycle 1, then daily from day 2 (before study
drug administration) through day 15, until the ANC reached
C2.0 9 109/L, or the patient was able to enter the next
chemotherapy cycle (ANC C1.5 9 109/L on day 1 of the
next cycle). In cycles 2–4, ANC assessments began on day 5.
A similar schedule was used for measuring body temperature
with a calibrated standard device. Blood ANC samples in
efficacy analyses were analyzed by local laboratories.
The primary efficacy measure was the DSN, defined as
days with grade 4 neutropenia (ANC \0.5 9 109/L) in
cycle 1. Secondary efficacy measures included DSN in
cycles 2, 3, and 4; incidence of FN, defined as axillary
body temperature [38.5 C for [1 h and ANC \0.5 9
109/L in cycles 1, 2, 3, and 4 and across all cycles; inci-
dence of severe neutropenia (grade 4; ANC \0.5 9
109/L) in cycles 1, 2, 3, and 4; depth of ANC nadir; time to
ANC recovery (the first day with ANC C2.0 9 109/L after
any day with ANC \2.0 9 109/L); and median ANC time
profiles.
Pharmacokinetic analysis
Blood samples for pharmacokinetic (PK) analysis were
taken from a subpopulation of 33 patients (6.0-mg pegfil-
grastim group, n = 7; 3.0, 4.5, and 6.0-mg lipegfilgrastim
groups, n = 11, n = 7, and n = 8, respectively) from
selected centers in cycles 1 and 4. Samples were collected
predose, 2, 4, and 8 h after study drug administration on
day 2, and on days 3, 4, 5, 6, 7, 8, 9, 12, and 15. Lipeg-
filgrastim and pegfilgrastim serum concentrations
were analyzed using a validated quantitative sandwich
immunoassay in compliance with good laboratory practice
at Cirion Biopharma Research Inc. (Laval, Quebec, Can-
ada). Standard PK parameters (area under the concentra-
tion–time curve [AUC], maximum serum concentration
[Cmax], time to Cmax [Tmax], apparent terminal elimination
half-life [T], AUC0-inf and AUC0-last) were calculated by
noncompartmental methods using WinNonlin 6.0 (Phar-
sight Corporation, St. Louis, MO).
Safety assessments
An independent data safety monitoring committee moni-
tored unexpected side effects. All adverse events (AEs)
were reported until 30 days after the last study drug
injection. Each AE was assessed by the investigator as
serious or non-serious. A serious AE was one that resulted
in death, was life-threatening, required inpatient hospital-
ization or prolongation of existing hospitalization, resulted
in persistent or significant disability/incapacity, was a
congenital anomaly/birth defect, or was an important
medical event that jeopardized the patient or required
medical intervention to prevent one of the previously listed
criteria. Safety assessments—which included blood sam-
ples for antibody determination, physical examinations,
and vital signs—were performed within 24 h before che-
motherapy in each cycle and at end of study. Blood sam-
ples for assessment of laboratory safety parameters
(hematology, platelets, and clinical chemistry) were col-
lected at baseline, on day 15 of each cycle, and at end of
study. All grade 3 and 4 non-hematologic toxicities and all
grade 4 hematologic toxicities (except white blood cell
counts and differential count) were considered AEs.
Statistical analysis
Summary statistics were calculated for each measure.
Poisson regression analyses, including treatment, region
(Eastern and Central Europe versus Russia and Ukraine),
type of therapy (adjuvant versus treatment for metastatic
disease), weight class (B60, [60 to B75, [75 kg), and
baseline ANC as covariates, were performed for primary
and secondary DSN measures as well as for ANC nadir and
recovery end points. In relation to incidence of neutrope-
nia, logistic regression analyses were performed with the
same cofactors used for Poisson regression analyses. For
mean DSN and secondary end points, 2-sided 95 % con-
fidence intervals (CIs) were calculated for the ratios of
expected values and for the odds ratios of all possible
comparisons between treatment groups. Chi-squared tests
were used to compare AEs among all four treatment
groups, and the Cochran–Armitage Trend test scrutinized
possible dose dependencies among lipegfilgrastim dose
groups.
Breast Cancer Res Treat (2014) 148:107–116 109
123
A post-hoc efficacy analysis assessed non-inferiority of
the lipegfilgrastim dose groups versus the pegfilgrastim
group for DSN in cycle 1. Poisson regression analyses with
identity link and analysis of covariance with possible het-
eroskedasticity, including treatment, region, therapy type,
weight class, and baseline ANC as covariates, were per-
formed. Bonferroni-adjusted 2-sided 98.3 % CIs were
calculated for least-squares mean differences in DSN in
cycle 1 for lipegfilgrastim versus pegfilgrastim. The
equivalence margin was set to ±1 day.
The number of patients per treatment group was not
based on formal statistical sample-size calculations but was
considered adequate to allow for determination of an
optimal lipegfilgrastim dose for phase 3 clinical studies. In
a previous study conducted in patients with breast cancer
treated with XM02 (Tevagrastim, Ratiograstim, Biog-
rastim, and GranixTM, Teva Pharmaceutical Industries
Ltd., Petach Tikva, Israel) or Neupogen (Amgen, Thou-
sand Oaks, CA, USA), a mean DSN of 1.1 days and a
standard deviation of 1.2 were observed in cycle 1 for both
drugs [15]. Assuming the same numbers for one of the
lipegfilgrastim groups and the pegfilgrastim group in the
present study, the 2-sided 95 % CI for the difference in
mean DSN between these 2 groups would have a maximal
width of ±0.5 with about 80 % probability. A Poisson
regression model for the previous study estimated the
variance to be about 1.25 times the mean. Thus, a mean
DSN of 0.5 would correspond to a standard deviation of
0.8, and a mean DSN of 2.0 would correspond to a standard
deviation of 1.6. Assuming the same relationship between
mean and variance in the present study, the difference
between 2 groups with mean DSN of 0.5 and 1.1 could be
detected with a power of 83 %, whereas the difference
between 2 groups with mean DSN of 1.1 and 2.0 could be
detected with a power of 88 %, both at the 2-sided 5 %
level.
Analysis populations
Demographic and baseline characteristics, efficacy vari-
ables, and post-hoc non-inferiority tests were evaluated for
the intent-to-treat (ITT) and per-protocol (PP) populations.
The full analysis population (ITT) comprised all patients
randomized to a study drug at the baseline visit. The PP
population comprised all patients in the ITT set who
completed C1 cycle of chemotherapy, received C1 dose of
study drug, and had no major protocol violations. The
safety population included all randomized patients who
received C1 dose of study medication and was identical to
the ITT population. The PK population comprised patients
from selected centers who had blood samples collected for
PK analysis in cycles 1 and 4.
Results
Study population
A total of 208 patients were randomized; 202 (97.1 %)
completed the study (Fig. 1). Of the 6 patients who with-
drew from the study, 3 withdrew because of AEs, 2 with-
drew consent, and 1 was lost to follow-up. All 208
randomized patients were treated with study drug and were
eligible for efficacy and safety analyses. Three patients had
major protocol violations (1 received the wrong study drug
dose and 2 received the wrong chemotherapy doses) and
were included in the ITT and safety populations only.
Demographic and baseline disease characteristics were
similar among treatment groups, with the majority of
patients having stage III (46.2 %) or high-risk stage II
disease (38.5 %; Tables 1, 2). The majority of patients
were aged\65 years and had ECOG performance status of
0 or 1.
Results in the PP population were similar to those in the
ITT population.
Efficacy
Duration of severe neutropenia in cycle 1
There was no significant difference in the DSN for cycle 1
among the 3 lipegfilgrastim doses, or between the lipeg-
filgrastim doses and the pegfilgrastim dose (Table 3). The
DSN in cycle 1 was consistently approximately 1 day or
less, with a pooled DSN of 0.89 days. The percentage of
patients who did not experience severe neutropenia was
higher in the lipegfilgrastim 6.0-mg group (62.0 %)
compared with the lipegfilgrastim 3.0- and 4.5-mg groups
and the pegfilgrastim group (43.4, 49.0, and 46.3 %,
respectively).
Post-hoc analyses established non-inferiority of lipeg-
filgrastim to pegfilgrastim for DSN in cycle 1. All three
98.3 % 2-sided CIs for least-squares mean differences
between lipegfilgrastim and pegfilgrastim were included in
the equivalence region between -1 and ?1 day. The upper
limit of the 98.3 % 2-sided CI for the difference between
lipegfilgrastim and pegfilgrastim was 0.28 days for lipeg-
filgrastim 6.0 mg, 0.29 days for lipegfilgrastim 4.5 mg, and
0.72 days for lipegfilgrastim 3.0 mg.
Duration of severe neutropenia in cycles 2–4
Mean DSN was consistently shorter in cycles 2–4 versus
cycle 1 in all treatment groups (Table 3). In the pooled
treatment group, C80 % of patients did not experience
severe neutropenia in cycles 2–4. However, incidence of
severe neutropenia was lower in the lipegfilgrastim groups
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compared with the pegfilgrastim group for each chemo-
therapy cycle. Mean DSN was significantly (P B 0.023)
shorter in the lipegfilgrastim 6.0-mg group versus the
pegfilgrastim group for chemotherapy cycles 2, 3, and 4.
Incidence of observed febrile neutropenia or severe
neutropenia
Only one patient in the pegfilgrastim group experienced FN
incycle 1. The incidence of severe (grade 4) neutropenia was
highest in cycle 1: 56.6 % with lipegfilgrastim 3.0 mg, 51.0 %
with lipegfilgrastim 4.5 mg, 38.0 % with lipegfilgrastim
6.0 mg, and 53.7 % with pegfilgrastim 6.0 mg. In all cycles,
incidence of severe neutropenia was lower with lipegfilgrastim
4.5 and 6.0 mg versus pegfilgrastim and lipegfilgrastim 3.0 mg
(data not shown), reaching significance versus pegfilgrastim in
chemotherapy cycles 2, 3, and 4 (P\0.05).
Absolute neutrophil count profiles
A dose-dependent trend was observed for ANC nadir
values, with lipegfilgrastim 6.0 mg being the most
Fig. 1 Patient disposition.
AE adverse event













Mean ± SD 53.1 ± 9.2 52.8 ± 10.1 51.4 ± 9.8 49.5 ± 11.1
B64, n (%) 46 (86.8) 45 (88.2) 45 (90.0) 50 (92.6)
65–74, n (%) 7 (13.2) 6 (11.8) 5 (10.0) 4 (7.4)
Weight (kg)
Mean ± SD 70.6 ± 13.1 70.6 ± 14.8 74.5 ± 19.7 71.2 ± 13.2
B60, n (%) 12 (22.6) 13 (25.5) 13 (26.0) 14 (25.9)
[60–B75, n (%) 24 (45.3) 20 (39.2) 19 (38.0) 18 (33.3)
[75, n (%) 17 (32.1) 18 (35.3) 18 (36.0) 22 (40.7)
Gender, n (%)
Female 52 (98.1) 50 (98.0) 50 (100.0) 53 (98.1)
Male 1 (1.9) 1 (2.0) 0 (0) 1 (1.9)
Reason for chemotherapy, n (%)
Adjuvant therapy 43 (81.1) 44 (86.3) 41 (82.0) 43 (79.6)
Treatment for metastatic disease 10 (18.9) 7 (13.7) 9 (18.0) 11 (20.4)
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Oncology Group, SD standard
deviation
ECOG performance status: 0,
fully active, able to carry on all
predisease performance without
restriction; 1, restricted in
physically strenuous activity but
ambulatory and able to carry out
work of a light or sedentary
nature, e.g., light housework,
office work; 2, ambulatory and
capable of all self-care but
unable to carry out any work
activities; up and about [50 %
of waking hours
Parameter Lipegfilgrastim Pegfilgrastim 6.0
mg (n = 54)
3.0 mg (n = 53) 4.5 mg (n = 51) 6.0 mg (n = 50)
Stage n (%)
High-risk stage II 21 (39.6) 19 (37.3) 18 (36.0) 22 (40.7)
Stage III 23 (43.4) 26 (51.0) 24 (48.0) 23 (42.6)
Stage IV 9 (17.0) 6 (11.8) 8 (16.0) 9 (16.7)
Tumor location, n (%)
Left 19 (35.8) 25 (49.0) 22 (44.0) 26 (48.1)
Right 31 (58.5) 25 (49.0) 27 (54.0) 27 (50.0)
Both 3 (5.7) 1 (2.0) 1 (2.0) 1 (1.9)
ECOG performance status, n (%)
0 34 (64.2) 26 (51.0) 28 (56.0) 33 (61.1)
1 18 (34.0) 22 (43.1) 21 (42.0) 21 (38.9)
2 1 (1.9) 3 (5.9) 1 (2.0) 0 (0)
Time since first diagnosis (months)
Mean ± SD 0.9 ± 0.9 5.4 ± 25.9 2.9 ± 10.2 16.1 ± 50.7
Median 1.0 1.0 1.0 1.0
Range 0.0–4.0 0.0–184.0 0.0–65.0 0.0–259.0
Table 3 Duration of severe
neutropenia, incidence of severe
neutropenia, depth of ANC
nadir, and time to ANC
recovery (intent-to-treat
population)
ANC absolute neutrophil count,
DSN duration of severe
neutropenia, SD standard
deviation
a P B 0.01 versus
pegfilgrastim
b P B 0.05 versus
pegfilgrastim










Cycle 1 DSN (days)
Mean ± SD 1.08 ± 1.12 0.84 ± 1.05 0.76 ± 1.10 0.87 ± 0.99
Median (range) 1.0 (0.0–4.0) 1.0 (0.0–4.0) 0.0 (0.0–3.0) 1.0 (0.0–3.0)
Mean DSN ± SD (days)
Cycle 2 0.32 ± 0.70 0.14 ± 0.49a 0.18 ± 0.39b 0.41 ± 0.63
Cycle 3 0.30 ± 0.67 0.20 ± 0.80 0.12 ± 0.39b 0.35 ± 0.71
Cycle 4 0.23 ± 0.51b 0.22 ± 0.78b 0.12 ± 0.44a 0.48 ± 0.91
Cycle 1: Incidence by duration [days], n (%)
0 23 (43.4) 25 (49.0) 31 (62.0) 25 (46.3)
1 10 (18.9) 15 (29.4) 6 (12.0) 16 (29.6)
2 14 (26.4) 6 (11.8) 7 (14.0) 8 (14.8)
3 5 (9.4) 4 (7.8) 6 (12.0) 5 (9.3)
4 1 (1.9) 1 (2.0) 0 (0.0) 0 (0.0)
Total 53 (100.0) 51 (100.0) 50 (100.0) 54 (100.0)
Incidence of severe neutropenia, n (%)
Cycle 1 30 (56.60) 26 (50.98) 19 (38.00) 29 (53.70)
Cycle 2 11 (20.75) 4 (7.84)c 9 (18.00)b 18 (33.96)
Cycle 3 10 (18.87) 3 (6.00)a 5 (10.00)b 13 (24.53)
Cycle 4 9 (17.31) 4 (8.33)b 4 (8.00)b 14 (26.42)
Cycle 1: Mean depth of ANC
nadir ± SD, 109/L
0.86 ± 1.08 1.33 ± 1.66 1.67 ± 1.99c 0.93 ± 1.30
Cycle 1: mean time to ANC
recovery ± SD, days
7.32 ± 3.07 6.10 ± 3.92 5.80 ± 3.96b 7.44 ± 3.01
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effective dose and the only dose where the depth of ANC
nadir was significantly higher versus pegfilgrastim for all
chemotherapy cycles (P B 0.05). Some significant trends
indicated longer time to ANC nadir with higher lipegfil-
grastim doses (P \ 0.05 for cycles 1, 3, and 4). Time to
ANC recovery was shortest with lipegfilgrastim 6.0 mg, for
which ANC recovery times were significantly shorter
versus pegfilgrastim in all chemotherapy cycles (P \ 0.05).
The course of median ANC over time in cycle 1 is shown
in Fig. 2.
Pharmacokinetics
Pharmacokinetic parameters are summarized in Table 4.
Lipegfilgrastim serum concentrations in cycle 1 peaked at
approximately 48 h and returned to predose levels within
240 h. A dose-dependent trend was evident for most PK
parameters, with mean values for the lipegfilgrastim 6.0-
and 4.5-mg doses being higher versus pegfilgrastim
(Table 4). Lipegfilgrastim Tmax was notably higher than
pegfilgrastim in cycle 1, but by cycle 4, influenced by
neutrophil-dependent elimination, Tmax for lipegfilgrastim
was closer to pegfilgrastim.
Safety
Adverse events were similar among treatment groups, with
no dose-dependent lipegfilgrastim trend (Table 5). The
overall frequency of AEs decreased with each chemo-
therapy cycle. The most commonly occurring AEs (total
Fig. 2 Median absolute
neutrophil count time profiles in
cycle 1
Table 4 Summary of pharmacokinetic (PK) parameters by treatment and cycle (PK population)
Parameter (mean) Cycle Lipegfilgrastim Pegfilgrastim 6.0 mg (n = 7)
3.0 mg (n = 11) 4.5 mg (n = 7c) 6.0 mg (n = 8)
Cmax, ng/mL
a 1 44.91 142.71 156.74 138.61
4 24.37 47.90 36.24 42.71
AUC0-last, ng//mL•ha 1 3475.8 11,880.1 13,328.2 8613.0
4 1416.1 2959.7 2632.1 2598.4
AUC0-inf, ng/mL•ha 1 3496.4 9608.7 13,342.3 8623.5
4 1424.4 2980.8 2657.0 2607.5
Tmax, h
b 1 52.2 59.0 53.0 17.7
4 22.5 16.0 11.4 23.4
T, h
b 1 36.7 31.2 29.3 29.5
4 35.4 32.0 38.9 29.6
AUC0-last area under the concentration–time curve from predose on day 2 to last observed concentration value above the lower limit of
quantification, AUC0-inf area under the concentration–time curve from predose on day 2 to infinity, Cmax maximum serum concentration, h hours,
T apparent terminal elimination half-life, Tmax time to maximum serum concentration
a Results for Cmax, AUC0-last, and AUC0-inf are geometric means
b Results for Tmax and T are arithmetic means
c N = 6 for all parameters in cycle 4 and for AUC0-inf and T in cycle 1
Breast Cancer Res Treat (2014) 148:107–116 113
123
incidence C10 % in the pooled treatment group) were:
alopecia (47.6 %), nausea (42.3 %), asthenia (24.5 %),
bone pain (19.2 %), diarrhea (18.3 %), fatigue (17.8 %),
anorexia (16.8 %), vomiting (13.5 %), headache (10.6 %),
and myalgia (10.1 %).
None of the patients died during the study. Serious AEs
were reported in 10 (4.8 %) patients. One patient in the
lipegfilgrastim 3.0-mg group experienced pyrexia; 3 patients
in the lipegfilgrastim 4.5-mg group experienced gastroen-
teritis, paronychia, and pneumonia (one AE in each patient),
and one patient in the 4.5-mg group experienced thrombo-
cytopenia, FN, and mucosal inflammation. One patient in the
lipegfilgrastim 6.0-mg group experienced FN and another
patient in the 6.0-mg group experienced asthenia and leu-
kocytosis. Three patients in the pegfilgrastim 6.0-mg group
experienced enterocolitis, FN, and uterine leiomyoma (one
AE in each patient). Four (1.9 %) patients experienced AEs
leading to discontinuation. Of these patients, one pegfilgra-
stim patient discontinued in cycle 1 because of headache,
malaise, and discomfort; however, the main reason for dis-
continuation was withdrawal of informed consent. One
lipegfilgrastim 3.0-mg patient discontinued in cycle 3
because of pyrexia, one lipegfilgrastim 4.5-mg patient
discontinued in cycle 2 because of pneumonia, and one
Table 5 Most frequent adverse
events by preferred term
















Alopecia 25 (47.2) 23 (45.1) 27 (54.0) 24 (44.4) 99 (47.6)
Nausea 21 (39.6) 20 (39.2) 22 (44.0) 25 (46.3) 88 (42.3)
Asthenia 12 (22.6) 16 (31.4) 14 (28.0) 9 (16.7) 51 (24.5)
Bone pain 9 (17.0) 9 (17.6) 10 (20.0) 12 (22.2) 40 (19.2)
Diarrhea 7 (13.2) 11 (21.6) 13 (26.0) 7 (13.0) 38 (18.3)
Fatigue 9 (17.0) 7 (13.7) 8 (16.0) 13 (24.1) 37 (17.8)
Anorexia 6 (11.3) 13 (25.5) 9 (18.0) 7 (13.0) 35 (16.8)
Vomiting 7 (13.2) 6 (11.8) 5 (10.0) 10 (18.5) 28 (13.5)
Headache 6 (11.3) 7 (13.7) 5 (10.0) 4 (7.4) 22 (10.6)
Myalgia 5 (9.4) 6 (11.8) 7 (14.0) 3 (5.6) 21 (10.1)
Stomatitis 5 (9.4) 4 (7.8) 6 (12.0) 4 (7.4) 19 (9.1)
Neutropenia 3 (5.7) 5 (9.8) 4 (8.0) 3 (5.6) 15 (7.2)
Arthralgia 4 (7.5) 5 (9.8) 2 (4.0) 2 (3.7) 13 (6.3)
Tachycardia 4 (7.5) 2 (3.9) 3 (6.0) 3 (5.6) 12 (5.8)
Abdominal pain upper 4 (7.5) 1 (2.0) 3 (6.0) 2 (3.7) 10 (4.8)
Thrombocytopenia 0 6 (11.8) 2 (4.0) 2 (3.7) 10 (4.8)
Back pain 2 (3.8) 4 (7.8) 2 (4.0) 1 (1.9) 9 (4.3)
Dizziness 2 (3.8) 5 (9.8) 1 (2.0) 1 (1.9) 9 (4.3)
Hypertension 4 (7.5) 2 (3.9) 3 (6.0) 0 9 (4.3)
Peripheral sensory
neuropathy
1 (1.9) 0 3 (6.0) 4 (7.4) 8 (3.8)
Viral respiratory tract
infection
1 (1.9) 1 (2.0) 1 (2.0) 5 (9.3) 8 (3.8)
Febrile neutropenia 0 2 (3.9) 3 (6.0) 2 (3.7) 7 (3.4)
Pharyngolaryngeal pain 0 3 (5.9) 2 (4.0) 2 (3.7) 7 (3.4)
Anemia 1 (1.9) 4 (7.8) 1 (2.0) 0 6 (2.9)
Constipation 0 3 (5.9) 2 (4.0) 1 (1.9) 6 (2.9)
Dysgeusia 1 (1.9) 0 1 (2.0) 4 (7.4) 6 (2.9)
Peripheral edema 0 2 (3.9) 3 (6.0) 1 (1.9) 6 (2.9)
Abdominal pain 1 (1.9) 2 (3.9) 2 (4.0) 0 5 (2.4)
Mucosal inflammation 0 2 (3.9) 0 3 (5.6) 5 (2.4)
Pyrexia 2 (3.8) 0 2 (4.0) 1 (1.9) 5 (2.4)
Rash 0 1 (2.0) 2 (4.0) 2 (3.7) 5 (2.4)
Decreased weight 1 (1.9) 1 (2.0) 3 (6.0) 0 5 (2.4)
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lipegfilgrastim 4.5-mg patient discontinued in cycle 3
because of thrombocytopenia, FN, mucosal inflammation,
and hemorrhagic disorder.
Laboratory assessments were consistent with the
underlying disease and the chemotherapy received, and did
not give rise to any safety concerns.
Discussion
In the present dose-finding study, patients experienced a
dose-dependent decrease in DSN during cycle 1 with
increasing lipegfilgrastim doses, with the most effective dose
being lipegfilgrastim 6.0 mg. In addition, lipegfilgrastim
6.0 mg had comparable efficacy with pegfilgrastim 6.0 mg,
for the DSN during cycle 1. Post-hoc analyses confirmed that
lipegfilgrastim 6.0 mg was non-inferior to pegfilgrastim
6.0 mg for reducing cycle 1 DSN in patients with breast
cancer receiving doxorubicin and docetaxel chemotherapy.
The DSN in cycle 1 for patients treated with lipegfilgrastim
6.0 mg and pegfilgrastim was 0.76 and 0.87 days, respec-
tively. This is shorter than that previously reported for peg-
filgrastim in patients with breast cancer receiving this
chemotherapy regimen (mean DSN, 1.3–1.8 days) [1, 9, 16].
However, unlike previous studies, the present study only
included chemotherapy-naive patients, which may have
contributed to the slightly shorter DSN.
The incidence of severe neutropenia in cycle 1 was
&50 % in the lipegfilgrastim 3.0- and 4.5-mg groups and in
the pegfilgrastim group. The incidence was lower in the li-
pegfilgrastim 6.0-mg group (38 %), which further supports
the use of this dose in clinical studies. Based on the definition
of ANC \0.5 9 109/L and a fever [38.5 C, only one
patient in the pegfilgrastim group experienced FN. The
incidence of FN was lower than that previously reported for
patients treated with pegfilgrastim (9–12 %) receiving the
same chemotherapy regimen [1, 9, 16]. The incidence of FN
was considerably lower than that of patients receiving
doxorubicin and docetaxel chemotherapy without G-CSF
support reported in a previous study wherein 40 % of
patients experienced FN defined as any grade 3 or 4 neu-
tropenia plus fever ([38 C) requiring antibiotics [17]. In
addition, in a previous study using the same chemotherapy
regimen and similar inclusion and exclusion criteria as the
current study, incidence of FN during cycle 1 was reduced by
about two-thirds, from 36 % in placebo patients to&12 % in
patients receiving G-CSF support [15]; the incidence was
still higher than that observed in the present study.
A dose-dependent trend for improved efficacy with
increasing lipegfilgrastim doses was apparent for most
secondary efficacy measures, including DSN cycles 3 and
4, mean time to ANC nadir, depth of ANC nadir, and ANC
recovery. In addition, significant differences between
lipegfilgrastim 6.0 mg and pegfilgrastim were observed for
several secondary efficacy measures; however, these data
should be interpreted with caution, because the observed
differences were small and the clinical relevance has not
been confirmed.
The design of the current study compares well with
previously published pivotal pegfilgrastim studies in breast
cancer patients receiving doxorubicin 60 mg/m2 and
docetaxel 75 mg/m2 every 3 weeks for 4 cycles [1, 9, 16].
In the present study, the highly myelotoxic doxorubicin and
docetaxel regimen was chosen to assess lipegfilgrastim
efficacy to prevent severe neutropenia because this che-
motherapy regimen is associated with a risk of FN of
approximately 35–40 % [15, 17], and G-CSF support is
clearly indicated [2, 5]. Breast cancer patients were chosen
because they represent a main cancer type in which G-CSF
is used, and because breast cancer patients were studied in
pivotal and dose-finding pegfilgrastim studies [1, 9, 16, 18].
While the present study only evaluated the efficacy and
safety of lipegfilgrastim in breast cancer patients, results
suggest that the potential for lipegfilgrastim to prevent
severe neutropenia may extend beyond this cancer type to
patients receiving myelosuppressive therapy. Pegfilgrastim
has been effective in reducing chemotherapy-induced
neutropenia in patients with breast cancer, colorectal can-
cer, lymphoma, lung cancer, and various other solid tumors
[19–21]. In addition, tbo-filgrastim, a short-acting recom-
binant G-CSF, has demonstrated comparable efficacy to
filgrastim for prophylaxis of chemotherapy-induced neu-
tropenia in patients with breast cancer, lung cancer, and
non-Hodgkin lymphoma [22].
Lipegfilgrastim PK results demonstrated a general dose-
dependent increase in drug exposure, reflected by increasing
Cmax and AUC values with increasing dose. The period of
sustained G-CSF concentrations coincided with the ANC
nadir, supporting the hypothesis that lipegfilgrastim has the
same neutrophil-mediated clearance mechanism of elimi-
nation as pegfilgrastim. This self-regulating property means
that a single dose can provide sufficient neutrophil support
for different durations of neutropenia [7, 16].
The safety profiles of lipegfilgrastim 6.0 mg and peg-
filgrastim 6.0 mg were comparable, and safety events were
not dose related. The incidence of TEAEs was expected in
this patient population and consistent with the underlying
disease and concomitant chemotherapy. No unexpected
new findings were observed. Bone pain was the most
common TEADR and is known to be associated with
G-CSF treatment. Fatigue, the second most common
TEADR, is frequently reported during chemotherapy.
In conclusion, lipegfilgrastim is a safe and effective
G-CSF support treatment in breast cancer patients receiv-
ing myelosuppressive chemotherapy with doxorubicin
and docetaxel. Lipegfilgrastim 6.0 mg, which is at least
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equivalent to the standard 6.0-mg fixed dose of pegfilgra-
stim with regard to DSN in this patient population, is the
optimal fixed dose for evaluation in phase 3 studies.
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